- CA$1.15bn
- CA$1.06bn
- CA$450.09m
Brief: Knight Therapeutics Inc - Samira Sakhia Will Assume Role Of President And Chief Executive Officer, Effective September 1, 2021
Canada Research Roundup: Gibson Energy, Well Health Technologies, Winpak
Knight Therapeutics: Up on deal to buy regional rights to Alzheimer's drug
Brief: Knight Therapeutics To Acquire Regional Rights To Exelon
Brief: Knight Therapeutics Reports Fourth Quarter And Year End 2020 Results
Brief: Knight Therapeutics Says Has Exclusive Right To Commercialize Ibsrela In Canada Under Terms Of A License Agreement Entered Into With Ardelyx
Brief: Knight Announces Filing Of Final Base Shelf Prospectus
Canada Stocks: TSX opens higher as energy, gold stocks rise
Brief: Knight Announces Filing Of Preliminary Base Shelf Prospectus
Canada Research Roundup: CES Energy Solutions, Fortuna Silver Mines, Total Energy Services
Brief: Knight Therapeutics Reports Third Quarter 2020 Results
Brief: Knight Signs New Exclusive Ambisome Agreement With Gilead In Brazil
Brief: Knight And Therapeuticsmd Announce Health Canada Approval Of Bijuva®
Brief: Knight Therapeutics Announces Filling Of Supplement To A New Drug Submission For Nerlynx®
Canada Research Roundup: Artemis Gold, National Bank of Canada, Royal Bank of Canada
Brief: Knight And Therapeuticsmd Announce Health Canada Approval Of Imvexxy®
Brief: Knight And Therapeuticsmd Announce Health Canada Approval Of Imvexxy®
Brief: Knight Therapeutics Inc - Qtrly Revenue $53.3 Million
Brief: Knight Announces Normal Course Issuer Bid